D-0875-2018 Class I Terminated
FDA drug recall D-0875-2018 was initiated by Allergan, PLC. on May 24, 2018 and is designated Class I. Reason for recall: Contraceptive Tablets Out of Sequence. The recall status is terminated (terminated May 19, 2022). Affected quantity: 168,768 blister cards (4,725,504 softgel capsules).
Recall Details
- Product Type
- Drugs
- Report Date
- Jun 20, 2018
- Initiation Date
- May 24, 2018
- Termination Date
- May 19, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 168,768 blister cards (4,725,504 softgel capsules)
Product Description
Allergan Taytulla Softgel Capsules, 1 mg/20 mcg, 6x28 blister card Physicians's Sample - Not for Sale Distributed by: Allergan USA INC Irvine, CA 92612 NDC 0023-5862-28 (Blister Card) NDC 0023-5862-29 (Blister Carton) NDC 0023-5862-31 (Outer carton) UPC 300235862290
Reason for Recall
Contraceptive Tablets Out of Sequence.
Distribution Pattern
US Nationwide
Code Information
Lot# 5620706, Exp. 05/19
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0875-2018
- openFDA file date
- Oct 6, 2026
- Loaded by RegDataLab
- Oct 12, 2026